A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

• ClinicalTrials.gov Identifier: NCT00453362
• Recruitment Status: Completed
• First Posted: March 28, 2007
• Results First Posted: October 3, 2011
• Last Update Posted: March 31, 2017
• Sponsor: Genentech, Inc.
• Collaborator: Roche Pharma AG
• Information provided by (Responsible Party): Genentech, Inc.

Study Description

Brief Summary:

This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography) imaging as a result of treatment with erlotinib in patients with recurrent or refractory non-small cell lung cancer (NSCLC). The study will enroll approximately 30 patients at approximately 4 sites in Australia and 2 sites in the United States.

Condition or disease	Intervention/treatment	Phase
Non-Small Cell Lung Cancer	Other: 2-deoxy-2-[18F]fluoro-D-glucose (FDG); Other: 3'-deoxy-3'-[18F]fluorothymidine (FLT); Drug: erlotinib HCl	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 88 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
• Study Start Date: December 2006
• Actual Primary Completion Date: April 2010
• Actual Study Completion Date: April 23, 2010

Arms and Interventions

Arm	Intervention/treatment
Experimental: Erlotinib; Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity. After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans.	Other: 2-deoxy-2-[18F]fluoro-D-glucose (FDG); FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).; Other: 3'-deoxy-3'-[18F]fluorothymidine (FLT); FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.; Drug: erlotinib HCl; Tablets taken orally 150 mg/day.; Other Name: Tarceva

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival (PFS) of Groups by FDG Response at Day 56 [ Time Frame: Time from first erlotinib treatment to disease progression on CT (per RECIST 1.0) or death, whichever occurs first, assessed up to 2 years ]

   PFS was defined as the time from the date of first erlotinib dose to disease progression or death, whichever occurs first.

   PFS was compared between patients with FDG-PET response and patients without FDG-PET response, independent of CT response (per RECIST 1.0) at Day 56 of treatment with erlotinib.

   Mean of the percent changes in maximal standard uptake values (mSUVmax) from FDG-PET scans was used to define FDG-PET response. Based on European Organization for Research on the Treatment of Cancer (EORTC) definitions, an objective FDG-PET response was defined an mSUVmax <-25%.

2. PFS of Patients With FDG-PET Complete Response (CR)/Partial Response (PR) Versus FDG-PET Progressive Disease (PD) in Patients With Computed Tomography (CT) Stable Disease (SD) at Day 56 [ Time Frame: Time from first erlotinib treatment to disease progression on CT (per RECIST 1.0) or death, whichever occurs first, assessed up to 2 years ]

   PFS was defined as the time from the date of first erlotinib dose to disease progression or death, whichever occurs first.

   PFS was compared between patients with FDG-PET response (Complete /Partial Responses) and patients with FDG-PET progression, within the subset of patients who demonstrated stable disease on CT (per RECIST 1.0) at Day 56 of treatment with erlotinib. FDG-PET response; defined as a mSUVmax from FDG-PET scans of <-25% and FDG-PET disease progression; defined as a mSUVmax >+25% or the development of a new lesion with a mSUVmax above background not explained by another cause.

3. Progression Free Survival of Groups by FLT Response at Day 56 [ Time Frame: Time from first erlotinib treatment to disease progression on CT (per RECIST 1.0) or death, whichever occurs first, assessed up to 2 years ]

   PFS was defined as the time from the date of first erlotinib dose to disease progression or death, whichever occurs first.

   PFS was compared between patients with FLT-PET response and patients without FLT-PET response, independent of CT response (per RECIST 1.0) at Day 56 of treatment with erlotinib.

   FLT-PET response was defined as a mSUVmax from FLT-PET scans <-25%.

4. Progression Free Survival of Patients With FLT CR/PR Versus FLT PD in Patients With CT SD at Day 56 [ Time Frame: Time from first erlotinib treatment to disease progression on CT (per RECIST 1.0) or death, whichever occurs first, assessed up to 2 years ]

   PFS was defined as the time from the date of first erlotinib dose to disease progression or death, whichever occurs first.

   PFS was compared between patients with FLT-PET response and patients without FLT-PET response, independent of computed tomography (CT) response (per RECIST 1.0) at Day 56 of treatment with erlotinib.

   FLT-PET response was defined as a mSUVmax from FLT-PET scans <-25% and FLT-PET disease progression was defined as a mSUVmax from FLT-PET scans >+25% or the development of a new lesion with a mSUVmax above background not explained by another cause.

5. Overall Survival of Groups by FDG Response at Day 56 [ Time Frame: From first erlotinib treatment to death, assessed up to 2 years ]

   Overall survival (OS) was defined as the time from the date of first erlotinib dose to death.

   Overall survival (OS) was compared between patients with FDG-PET response and patients without FDG-PET response, independent of Response Evaluation Criteria in Solid Tumors (RECIST 1.0) computed tomography (CT) response at Day 56 of treatment with erlotinib. FDG-PET response was defined as a mSUVmax from FDG-PET scans <-25%.

6. Overall Survival of Patients With FDG CR/PR Versus FDG PD in Patients With CT SD at Day 56 [ Time Frame: From first erlotinib treatment to death, assessed up to 2 years ]

   Overall survival (OS) was defined as the time from the date of first erlotinib dose to death.

   OS was compared between patients with FDG-PET response and patients with FDG-PET progression, within the subset of patients who demonstrated stable disease (SD) on CT (per RECIST 1.0) at Day 56 of treatment with erlotinib.

   FDG-PET response was defined as a mSUVmax from FDG-PET scans <-25% and FDG-PET disease progression was defined as a mSUVmax from FDG-PET scans >+25% or the development of a new lesion with a mSUVmax above background not explained by another cause.

7. Overall Survival of Groups by FLT Response at Day 56 [ Time Frame: From first erlotinib treatment to death, assessed up to 2 years ]

   Overall survival (OS) was defined as the time from the date of first erlotinib dose to death.

   OS was compared between patients with FLT-PET response and patients without FLT-PET response, independent of CT response (per RECIST 1.0) at Day 56 of treatment with erlotinib.

   FLT-PET response was defined as a mSUVmax from FLT-PET scans <-25%.

8. Overall Survival of Patients With FLT CR/PR Versus FLT PD in Patients With CT SD at Day 56 [ Time Frame: From first erlotinib treatment to death, assessed up to 2 years ]

   Overall survival (OS) was defined as the time from the date of first erlotinib dose to death.

   OS was compared between patients with FLT-PET response and patients with FLT-PET progression, within the subset of patients who demonstrated SD on CT (per RECIST 1.0) at Day 56 of treatment with erlotinib.

   FLT-PET response was defined as a mSUVmax from FLT-PET scans of <-25% and FLT-PET disease progression was defined as a mSUVmax from FLT-PET scans >+25% or the development of a new lesion with a mSUVmax above background not explained by another cause.

Secondary Outcome Measures :

1. Percentage of Patients With FDG-PET Responses [ Time Frame: Day 14 and Day 56 ]

   In patients with computed tomography (CT)-stable disease (according to RECIST 1.0) at 56 days of erlotinib treatment, the percentage of patients who demonstrated FDG-PET responses after the initial 14 days and 56 days of erlotinib treatment.

   FDG-PET response was defined as a mSUVmax from FDG-PET scans <-25%.

   CT SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started.

2. Percentage of Patients With FLT-PET Responses [ Time Frame: Day 14 and Day 56 ]

   In patients with CT-stable disease (according to RECIST 1.0) at 56 days of erlotinib treatment, the percentage of patients who demonstrated FLT-PET responses after the initial 14 days and 56 days of erlotinib treatment.

   FLT-PET response was defined as a mSUVmax from FLT-PET scans <-25%. CT SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started.

3. FDG Response in Subgroups by CT Response at Day 56 [ Time Frame: Day 56 ]

   In patients with partial response or progressive disease on CT (per RECIST 1.0) after 56 days of erlotinib treatment, the percentage of patients who demonstrated FDG-PET responses on Day 56 defined as a mSUVmax from FDG-PET scans <-25%.

   CT Partial Response defined as a 30% decrease in the sum of the longest diameter (LD) of target lesion taking as reference the baseline sum of the LD.

   CT Progressive disease defined as a 20% increase in the sum of the longest diameter of target lesions taking as reference the smallest sum LD since treatment started or appearance of 1 or more new lesions.

4. FLT Response in Subgroups by CT Response at Day 56 [ Time Frame: Day 56 ]

   In patients with partial response or progressive disease on CT (per RECIST 1.0) after 56 days of erlotinib treatment, the percentage of patients who demonstrated FLT-PET responses on Day 56 defined as a mSUVmax from FLT-PET scans <-25%.

   CT Partial Response defined as a 30% decrease in the sum of the longest diameter (LD) of target lesion taking as reference the baseline sum of the LD.

   CT Progressive disease defined as a 20% increase in the sum of the longest diameter of target lesions taking as reference the smallest sum LD since treatment started or appearance of 1 or more new lesions.

5. Number of Participants With Adverse Events Due to FLT-PET Imaging [ Time Frame: From screening to Day 112 assessment visit or study discontinuation or termination, whichever is first. On visits after Day 112, only SAE were recorded. ]
   The number of participants who experienced an adverse event judged by the investigator to be related to FLT-PET.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Signed Informed Consent Form(s)
• Histologically confirmed NSCLC
• Recurrent or progressive disease after receiving at least one chemotherapy regimen for advanced or metastatic NSCLC
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• Age ≥ 18 years
• Recovery from reversible acute effects of prior anti-cancer therapy (chemotherapy, radiotherapy, or investigational treatment) to NCI Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≤ 1 (excluding alopecia)
• Ability to comply with the study and follow-up procedures, including all specified imaging studies
• Ability to take oral medication
• Availability of archival diagnostic paraffin-embedded tumor tissue and willingness to provide sufficient tissue for testing for EGFR levels in tumor by both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
• Life expectancy ≥ 3 months
• Measurable disease on computed tomography (CT)
• At least one detectable lesion on FDG-PET scan and/or FLT-PET scan that is measurable on CT
• Use of an acceptable means of contraception (men and women of childbearing potential) or documentation of infertility

Exclusion Criteria:

• Prior treatment with an investigational or marketed agent for the purpose of inhibiting epidermal growth factor receptor (EGFR) (including, but not limited to, erlotinib and gefitinib)
• Chemotherapy, radiotherapy, or investigational treatment within 14 days or within 5 half-lives of the active molecules in the chemotherapy or investigational treatment, whichever is longer, prior to study entry or from which patients have not yet recovered
• Inability to take oral medications, disease affecting gastrointestinal absorption, or prior surgical procedure affecting gastrointestinal absorption
• Uncontrolled diabetes
• Any unstable systemic disease (including active infection, unstable angina, congestive heart failure, myocardial infarction within 1 month prior to study entry, hepatic, renal, or metabolic disease)
• Pregnancy or lactation
• History of another malignancy in the past 2 years, unless the malignancy has been adequately treated, is currently not detectable, and is associated with a 5-year survival > 90%
• Claustrophobia
• Any other disease, condition, physical examination finding, or clinical laboratory finding which, in the opinion of the investigator, makes the patient inappropriate for the study

Contacts and Locations

Sponsors and Collaborators

Genentech, Inc.

Roche Pharma AG

Investigators

• Study Director: Bernard Fine, M.D.; Genentech, Inc.

More Information

• Responsible Party: Genentech, Inc.
• ClinicalTrials.gov Identifier: NCT00453362
• Other Study ID Numbers: OSI3926g; ML20773
• First Posted: March 28, 2007
• Results First Posted: October 3, 2011
• Last Update Posted: March 31, 2017
• Last Verified: October 2011

Keywords provided by Genentech, Inc.:

NSCLC; Tarceva; Positron emission technology; PET; Computerized tomography; CT

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Erlotinib Hydrochloride; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action